导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.87% | 1995/4773 |
| 近一周 | -3.19% | 3855/5462 |
| 近一月 | -10.11% | 4972/5421 |
| 近一季 | -18.93% | 4775/5209 |
| 近半年 | -1.81% | 1697/4920 |
| 近一年 | 5.22% | 1626/4366 |
| 近两年 | 106.52% | 534/2954 |
| 近三年 | 60.53% | 435/2253 |
| 成立以来 | 77.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.13% 2141/4961 |
34.89% 943/5312 |
- - |
- - |
| 2025 | 48.18% 537/4813 |
-1.92% 2817/3635 |
2.93% 1254/4076 |
48.36% 380/4524 |
-1.07% 2804/4813 |
| 2024 | 13.69% 1116/3463 |
-4.33% 1641/2808 |
-6.27% 1901/3014 |
26.42% 263/3129 |
0.29% 1234/3463 |
| 2023 | -18.65% 1821/2656 |
1.86% 1496/2280 |
-6.95% 1747/2385 |
-9.08% 1774/2515 |
-5.60% 1413/2655 |
| 2022 | -28.49% 1563/2207 |
-19.35% 1447/1919 |
5.28% 928/2016 |
-17.47% 1601/2113 |
2.06% 1054/2208 |
| 2021 | 10.67% 422/1822 |
-6.93% 1049/1255 |
24.69% 109/1330 |
-6.65% 975/1466 |
2.16% 670/1822 |
| 2020 | 58.37% 136/1250 |
2.59% 132/1028 |
28.42% 106/1067 |
5.40% 920/1164 |
14.06% 304/1184 |
| 2019 | 38.00% 323/1092 |
30.56% 240/739 |
-9.36% 647/788 |
6.86% 113/850 |
9.13% 255/918 |
| 2018 | -25.32% 346/834 |
- - |
-13.54% 450/631 |
-10.72% 546/660 |
-10.35% 192/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发创业板ETF发起式联接C VS. 长安沪深300非周期A(740101) |